The Lankenau Institute for Medical Research
Cardiovascular
disease is the most prominent killer in the U.S. after cancer. LIMR
researchers focus on developing new drugs and devices to correct heart
beat disorders, treat and prevent heart attacks and strokes, and avert
heart failure. Some work is also dedicated to monitoring and analyzing
our clinical progress in improving patient outcomes. In our basic
research component, we study underlying causes of high blood pressure
(hypertension) and a unique class of stem cells studied at LIMR that may
be useful for cardiac regeneration.
Robert Cox, PhD – hypertension, calcium channels, potassium channel function, atherosclerosis
Donglin Guo, MD, PhD - heart failure, arrhythmias, electrophysiology, ion channels, patch clamp
Peter R. Kowey, MD – arrhythmia, electrophysiology, atrial fibrillation, sudden cardiac death, antiarrhythmic drugs, cardiac pharmacology, anticoagulants, cardiac toxicity of non-cardiac drugs
Lisa D. Laury-Kleintop, PhD – atherosclerosis, negative tissue remodeling, statins, cardiomyopathy, diabetes
Melvin Reichman, PhD (LIMR Chemical Genomics Center) - drug discovery, high throughput screening, molecular pharmacology, chemical diversity
Gan-Xin Yan, MD, PhD - rapid and irregular heartbeat, myocardial infarction, enlarged and weakened heart, abnormal heart rhythms
Li Zhang, MD – inherited arrhythmias, cardiovascular outcomes
© 2013 Lankenau Institute for Medical Research. All rights reserved. | Terms of Use | Privacy Policy